22 withdrawn, 13 terminated, 10 recruiting, 8 active not recruiting. 68 Phase 2, 32 Phase 1, 2 Phase 3.
Follow ALT-803: new trials by email Literature Review of ALT-803 trials Research Report on ALT-803
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-11-04 | 2026-10-30 |
| Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance TriAdeno vaccine, N-803 - Adenocarcinoma, Prostate Cancer | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 52 | 2026-11-04 | 2026-10-30 |
| NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis Nogapendekin alfa inbakicept (NAI), Placebo - Sepsis | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 50 | 2026-10-15 | 2026-09-25 |
| IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy N-803, ETBX-71 Vaccine, 18F-DCFPyL - Recurrent Prostate Cancer, Prostate Cancer | Phase 2 | Recruiting | National Cancer Institute (NCI) | 65 | 2026-10-01 | 2026-10-06 |
| First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept - Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 26 | 2026-07-07 | 2026-07-10 |
| NAI for Sepsis With Persistent Lymphopenia Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC) - Sepsis, Septic Shock | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 50 | 2026-07-06 | 2026-05-11 |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma CD19 t-haNK- IV Administration, N-803, rituximab - Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2026-04-01 | 2026-03-17 |
| Immunotherapy Before and After Surgery N-803, ETBX-071, M-CENK - High-risk Prostate Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2025-12-15 | 2026-05-05 | |
| Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells) - High-risk Prostate Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2025-12-01 | 2026-05-05 | |
| A Study to Assess Anktiva in Patients With Long Covid-19. N-803 (IL-15 Superagonist) - Long COVID | Phase 2 | Recruiting | ImmunityBio, Inc. | 20 | 2025-11-14 | 2026-05-11 |
| A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma Temozolomide, Irinotecan, hu14.18K322A - Neuroblastoma Recurrent | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 54 | 2025-11-10 | 2026-08-07 |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer N-803 and BCG, N-803 and Gemcitabine - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2025-11-01 | 2025-10-16 |
| Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma PD-L1 t-haNK cells, pembrolizumab, N-803 - Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2025-09-24 | 2026-09-18 |
| A Study to Examine Anktiva for the Treatment of COVID-19. Anktiva - Long COVID, Long COVID Syndrome | Phase 2 | Recruiting | ImmunityBio, Inc. | 40 | 2025-09-04 | 2026-09-24 |
| Interleukin-15 to Promote Post-ART Control of HIV N-803, Saline placebo - HIV | Phase 2 | Enrolling by invitation | Michael Peluso, MD | 20 | 2025-08-19 | 2026-01-22 |
| A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer Gemcitabine, N-803, M-CENK - Platinum-resistant Ovarian Cancer | Phase 2 | Recruiting | ImmunityBio, Inc. | 20 | 2024-11-06 | 2026-07-01 |
| N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma Bevacizumab, PD-L1 t-haNK, N-803 - Glioblastoma | Phase 2 | Active not recruiting | ImmunityBio, Inc. | 34 | 2024-08-07 | 2026-07-01 |
| Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer AdHER2DC vaccine, Pembrolizumab, N-803 - Endometrial Cancer, Cancer of Endometrium | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-05-14 | 2026-10-16 |
| N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer Bintrafusp alfa, N-803, BN-Brachyury - Castration Resistant Prostate Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-04-01 | 2024-04-02 |
Showing 20 of 68. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (8) · Pancreatic Neoplasms (7) · Colorectal Neoplasms (5) · Leukemia, Myeloid, Acute (5) · Prostatic Neoplasms (5) · Carcinoma, Merkel Cell (4) · Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma, Transitional Cell (3) · Myelodysplastic Syndromes (3) · Non-Muscle Invasive Bladder Neoplasms (3) · Sepsis (3) · Triple Negative Breast Neoplasms (3) · Acquired Immunodeficiency Syndrome (2) · Carcinoma (2)
ImmunityBio, Inc. (39) · National Cancer Institute (NCI) (11) · Masonic Cancer Center, University of Minnesota (4) · Washington University School of Medicine (4) · Altor BioScience (1) · Dana-Farber Cancer Institute (1) · Medical University of South Carolina (1) · Michael Peluso, MD (1) · NantCell, Inc. (1) · SWOG Cancer Research Network (1) · St. Jude Children's Research Hospital (1) · Thai Red Cross AIDS Research Centre (1) · University of Arkansas (1) · University of Minnesota (1)
United States (50) · India (1) · South Africa (1) · Thailand (1)
Bobby Reddy, MD (3) · Amanda Cashen, M.D. (2) · Bruce Brown (2) · Charalampos Floudas, M.D. (2) · Hoyoung Maeng, M.D. (2) · James L Gulley, M.D. (2) · Claudio Brunstein, MD, PhD (1) · Daniel Morgensztern, M.D. (1) · David S Schrump, M.D. (1) · Frits van Rhee, MD, PhD (1) · Giordano Fabricio Cittolin Santos, MD, PhD (1) · Hoyoung M Maeng, M.D. (1) · Jeffrey Miller, MD (1) · Jeffrey S. Miller, MD (1) · John M Wrangle (1)
PMID 34797911, PMID 38953850, PMID 29463563, PMID 29628312, PMID 30227893, PMID 33602696, PMID 33720067, PMID 33832946, PMID 35196021, PMID 35727629, PMID 40156838, PMID 40956664, PMID 41520164, PMID 42498485
F32CA200253 (1), P50CA171963 (1), U10CA180888 (1)